P-31 changes as a measure of therapy response in resistant and sensitive osteosarcomas implanted into nude mice

✍ Scribed by J.R. Ballinger; H. Kang; C.A. Sweeney; J.D. Scott; B.P. Croker; K.N. Scott

• Publisher: Elsevier Science
• Year: 1995
• Tongue: English
• Weight: 734 KB
• Volume: 13
• Category: Article
• ISSN: 0730-725X
• DOI: 10.1016/0730-725x(95)00035-f

✦ Synopsis

Objective: To determine if changes in PCr/Pi and PME can be used to predict lack of tumor response to chemotherapy in a murine model of a chemotherapy-resistant human osteosarcoma. Material and Methods: Cisplatinresistant sublhtes were grown from high-grade cisplatin-sensitive human osteosarcoma. Surface coil localized 31P NMR spectroscopy of implanted cisplatin-resistant and sensitive osteosarcoma tumors in nude mice was performed. Results: A cisplatin-resistant subline of a sensitive human osteosarcoma was developed that was five times more resistant to cisplatin than the parent cell line. Our NMR data shows a statistically significant difference in the change in the PCr/Pi ratio after treatment between sensitive and resistant osteosarcomas at the 01 = 0.05 level. Changes in PME were seen in the sensitive tumors but were not statistically significant. Conclusions: Changes in PCr/Pi predict lack of tumor treatment response in human osteosarcoma implanted into nude mice with a specificity of 70% and a sensitivity of 54%. Monitoring of PCr/Pi in human osteosarcoma patients may allow detection of response to chemotherapy before conventional imaging techniques.